Loading
CRISPR and Genetic Engineering · Journal article
Acs Sensors · September 8, 2026
Encouraging direction, but not yet definitive.
This prospective multicenter study reports a CRISPR-based diagnostic platform that achieved 100% positive percent agreement with blood culture for S. aureus detection (20/20 cases) directly from whole blood in approximately 2 hours, compared to the standard 3–7 days. However, the evaluation enrolled only 8 MRSA-positive cases and does not report specificity, negative predictive value, or performance in clinically relevant subgroups, limiting evidence of clinical utility.
Prospective multicenter clinical evaluation. Hospitalized patients with suspected bacteremia undergoing evaluation for bloodstream infection.. Intervention: CRISPR-based diagnostic assay (HELP platform) targeting S. aureus nucA and mecA genes with dual-gene detection, performed directly from whole blood.. Compared with: Blood culture (reference standard). n = 350. Multicenter (specific locations not stated in abstract).
Platform identified all 20 S. aureus-positive cases including 8 MRSA-positive cases, demonstrating 100% positive percent agreement with blood culture Detection time reduced from >70 hours (standard blood culture) to approximately 2 hours (HELP platform) Assay sensitivity of 10 copies/reaction with no cross-reactivity reported
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If confirmed in larger studies with adequate MRSA prevalence, this rapid detection platform could enable earlier targeted therapy for MRSA bloodstream infections. Clinicians should recognize that sensitivity appears excellent, but specificity and negative predictive value remain unreported, and the study enrichment for bacteremia-suspected patients may not reflect general populations.
A prospective multicenter clinical evaluation demonstrating 100% sensitivity for S. aureus detection in 350 patients with suspected bacteremia, but limited by small MRSA case numbers (n=8) and lack of specificity data, requiring confirmation in larger MRSA-enriched cohorts before clinical implementation.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in larger studies with adequate MRSA prevalence, this rapid detection platform could enable earlier targeted therapy for MRSA bloodstream infections. Clinicians should recognize that sensitivity appears excellent, but specificity and negative predictive value remain unreported, and the study enrichment for bacteremia-suspected patients may not reflect general populations.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of mortality in critically ill patients with bloodstream infections (BSIs). Timely diagnosis and early initiation of guideline-concordant antimicrobial therapy are independently associated with improved survival and reduced complication rates in patients with MRSA BSIs. However, current blood culture-based detection of MRSA requires 3–7 days for definitive identification and antimicrobial susceptibility reporting, entails numerous manual steps, and frequently delays the transition from empirical to pathogen-directed therapy, thereby affecting treatment outcomes and patient prognosis. Here, we present a highly sensitive and specific CRISPR-based diagnostic platform that shortens the MRSA detection time from >70 h to ∼2 h—enabling true "sample-to-result" testing directly from whole blood at the point of care. This study develops a one-step RPA-CRISPR assay targeting the S. aureus nucA and mecA genes, with 10 copies/reaction sensitivity and no cross-reactivity. By integrating vancomycin-conjugated magnetic nanoparticles, a herringbone microfluidic chip, and a miniaturized wireless analyzer, the platform performs on-chip S. aureus capture, lysis-mediated DNA release, and dual-gene detection directly from whole blood. In a prospective, multicenter clinical evaluation of 350 hospitalized patients with suspected bacteremia, the HELP platform identified all 20 S. aureus-positive cases (including 8 MRSA-positive cases), demonstrating 100% positive percent agreement with blood culture. By delivering definitive MRSA identification in under 2 h, HELP markedly accelerates clinical decision-making, facilitates the timely initiation of targeted antimicrobial therapy, and holds strong potential for scalable deployment in primary care and resource-constrained settings.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.